WallStSmart

Ekso Bionics Holdings Inc (EKSO)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 23918% more annual revenue ($3.07B vs $12.80M). WST leads profitability with a 16.1% profit margin vs -91.4%. WST earns a higher WallStSmart Score of 55/100 (C-).

EKSO

Avoid

20

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -13.03

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EKSO.

WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EKSO0 strengths · Avg: 0/10

No standout strengths identified

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

EKSO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$37.56M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-107.6%2/10

ROE of -107.6% — below average capital efficiency

Revenue GrowthGrowth
-38.3%2/10

Revenue declined 38.3%

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : EKSO

EKSO has a balanced fundamental profile.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : EKSO

The primary concerns for EKSO are EPS Growth, Market Cap, Return on Equity.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

EKSO profiles as a turnaround stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 7.5% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

WST scores higher overall (55/100 vs 20/100), backed by strong 16.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ekso Bionics Holdings Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company is headquartered in Richmond, California.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?